Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-Year Period in Patients With Schizophrenia
This study has been completed.
Study NCT00299702   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: March 3, 2006   Last Updated: July 8, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
Psychotic Disorders
More general conditions related to this trial
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
Abilify
Risperidal Consta
Additional drug interventions recognized in this trial
Aripiprazole
Risperidone
More general drug interventions related to this trial
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.
Janssen, LP


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services